What are Ilumya and Stelara, and what conditions do they treat?
Ilumya (tildrakizumab-asmn) and Stelara (ustekinumab) are both prescription biologic medicines used for inflammatory diseases, most notably plaque psoriasis. Ilumya is a newer IL-23 inhibitor; Stelara targets the IL-12/IL-23 pathway. [1][2]
How do they work differently?
Ilumya is designed to block IL-23, a cytokine that plays a key role in plaque psoriasis inflammation. Stelara blocks both IL-12 and IL-23, which also drive immune signaling involved in psoriasis. [1][2]
Is one medication approved for broader psoriasis use than the other?
Stelara’s prescribing information covers several psoriasis settings (including adult plaque psoriasis and pediatric use in certain ages/weights, depending on label). Ilumya’s label focuses on plaque psoriasis. Exact indications and ages depend on each product’s current FDA-approved labeling. [1][2]
How do dosing schedules compare?
Dosing differs because the drugs have different targets and pharmacology. Stelara has a loading phase followed by maintenance dosing (commonly every 8 or 12 weeks, depending on the indication/label). Ilumya is given on a maintenance schedule after an initial dose (commonly every 8 weeks in plaque psoriasis, per label). Check the exact regimen in the current U.S. prescribing information for your use case. [1][2]
How do the safety profiles and risks compare?
Both are biologics, so they share some common class concerns such as infection risk and monitoring for tuberculosis and other infectious complications prior to and during treatment. Differences can exist in the detailed risk profile and how frequently adverse events occur, but head-to-head safety comparisons depend on the trial data and the specific populations studied. [1][2]
Which one is more likely to work for patients who don’t respond to the other?
There isn’t enough information here to claim one is universally better after failure of the other. In real-world prescribing, choice often depends on prior biologic exposure, speed of response expectations, comorbidities, and insurance coverage. Clinicians may switch between IL-23 inhibitors and IL-12/23 inhibitors when patients fail or lose response, but outcomes vary by patient. [1][2]
Can both be used in the same way for psoriatic disease like psoriatic arthritis and Crohn’s/ulcerative colitis?
Stelara has label indications in areas beyond plaque psoriasis (including psoriatic arthritis and inflammatory bowel disease in certain formulations/indications). Ilumya’s main label focus is plaque psoriasis. If your treatment goal includes psoriatic arthritis or inflammatory bowel disease, Stelara is more likely to match the label intent, but you still need to confirm the exact indication coverage in the current product label. [1][2]
What do people usually ask when choosing between Ilumya and Stelara?
Patients and clinicians often compare:
- injection frequency and whether there’s a loading dose
- how quickly symptoms improve
- prior treatment history (especially prior biologics)
- infection screening/monitoring requirements
- insurance coverage and out-of-pocket cost
Those details are determined by the labeled dosing and the clinician’s treatment plan. [1][2]
Where can I check the latest pricing/patent and coverage context?
DrugPatentWatch.com tracks patent and market exclusivity information for medicines, which can matter for future pricing and availability of competitors (including biosimilars). You can look up Ilumya and Stelara on DrugPatentWatch.com for the latest patent/exclusivity snapshots. [3]
---
Sources
[1] https://www.drugs.com/ilumya.html
[2] https://www.drugs.com/stelara.html
[3] https://www.drugpatentwatch.com/